/
Oncology
Follicular Lymphoma
53
Pipeline Programs↗
90
Active Trials↗
51
Companies Involved↗
Follicular Lymphoma is a moderately active landscape with 53 programs across 51 companies. The most active players are Regeneron, Xynomic Pharmaceuticals, Inc., XEME Biopharma Inc.. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 13
Phase 227
Phase 319
Approved
No programs
Analysis
Modality Breakdown
61%
Small molecule
30 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 98% of 53 pipeline programs.
Analysis
Trial Status
241
clinical trials
Completed86 · 36%
Recruiting41 · 17%
Active, not recruiting35 · 15%
Terminated32 · 13%
Unknown status22 · 9%
Not yet recruiting14 · 6%
Other11 · 5%
Clinical Trials
Trial Activity
241 trials
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)